Clinical trials
General Population (no Specific Condition or Disease) clinical trials
Below are recruiting general population (no specific condition or disease) clinical trials, each written for real people, not researchers. We’re tracking 10,803 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05272202RecruitingEarly Phase 1
Study brain signals after median nerve stimulation during anesthesia
This early-stage study checks how brain activity changes when the median nerve is gently stimulated while you’re under general anesthesia with propofol. It may help researchers better understand brain–nerve connections and improve how these signals are measured.
BrusselsAges 18–81 - NCT05443425RecruitingPhase 1
Leflunomide plus steroids for acute graft-versus-host disease
This early-phase trial tests whether adding leflunomide to standard steroid treatment can better control acute graft-versus-host disease (aGvHD) after a stem cell transplant. It may help reduce the immune reaction that damages the body while keeping treatment safe and manageable.
Duarte, CaliforniaAges 18 years+ - NCT05179863Recruiting
Swiss rare disease registry for patients and caregivers
This study builds a “registry,” which is a secure list of people with rare diseases or suspected rare diseases in Switzerland. It helps researchers better understand these conditions over time and improve care.
AarauAges Any age - NCT05071131Recruiting
Inulin supplement to improve gut health in kidney disease
This trial studies whether taking inulin—a dietary fiber—can improve gut bacteria and the gut barrier in people with end-stage kidney disease on hemodialysis. It may help reduce gut-related problems that can affect overall health in kidney disease.
BerlinAges 18–75 - NCT04954404Recruiting
Mitral valve procedure registry for Chinese patients in one center
This study is a registry (a way to track real-world outcomes) for people with mitral valve disease who receive a mitral valve procedure. It helps doctors understand how well these procedures work and what complications happen in patients like you.
Hangzhou, ZhejiangAges 18 years+ - NCT05139719RecruitingPhase 2
HEC585 trial for slowing lung scarring decline
This Phase 2 study tests whether HEC585 can slow the decline in lung function in people with progressive fibrosing interstitial lung disease (PF-ILD). It may help preserve breathing capacity and breathing tolerance over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05238792RecruitingPhase 1
Immune cells to treat high-risk solid tumors in children
This trial tests a type of immunotherapy using special white blood cells (T-cells) that are trained to find and attack cancer cells. It is for children and young adults with high-risk solid tumors that have not gone away or have come back after standard treatment.
Washington D.C., District of ColumbiaAges 1–70 - NCT04629833RecruitingPhase 3
Mesenchymal cells vs standard care for steroid-resistant graft-versus-host disease
This trial studies a type of immune-support cell therapy (mesenchymal stromal cells) compared with the best available standard treatment for acute graft-versus-host disease (aGvHD) that does not respond to steroids. It may help by calming an overactive immune reaction after a stem cell transplant.
AmiensAges 12 years+ - NCT04760522Recruiting
Genetic testing plan for patients with unclear disease cause
This study helps decide treatment planning based on genetic testing for people whose disease cause is unclear but may be genetic. It’s meant to support a “genomic health” approach, where results guide next steps in care.
TübingenAges Any age - NCT05458934Recruiting
Breath test study for adults with lung or airway conditions
This study analyzes breath samples from adults with lung or airway problems. It may help researchers understand these conditions better by looking at what’s in your exhaled breath.
Zurich, Canton of ZurichAges 18 years+ - NCT04991831Recruiting
Registry study for Exablate thalamotomy in tremor-dominant Parkinson’s
This study follows people who are getting an Exablate procedure to treat medication-resistant, tremor-dominant Parkinson’s. It aims to track safety and outcomes in real-world care after the treatment is approved.
Miami, FloridaAges 30–99 - NCT04397159Recruiting
Exercise program to reduce tiredness in some kidney patients
This trial studies whether doing a combination exercise program can reduce “fatigability,” meaning feeling unusually tired or weak during activity, in Veterans with moderate-to-advanced chronic kidney disease. It also compares results with people without kidney disease and checks for safety, especially for heart and joint health.
Washington D.C., District of ColumbiaAges 50–85 - NCT04731857Recruiting
Genetic testing results study for rare diseases
This study looks at how well different genetic tests (whole exome/genome sequencing and standard genetic tests) work for diagnosing rare genetic diseases and inherited cancer conditions. It may help confirm which testing approach provides the clearest results for families.
TübingenAges Any age - NCT04529629Recruiting
Tests and tracks treatment for adrenal hormone tumor diseases
This trial studies how adrenal hormone tumor diseases should be diagnosed, treated, and followed over time. It may help people get more precise care and better prediction of outcomes, but it has specific health and medication requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT03859895Enrolling by invitation
Zoledronate to help prevent Paget’s disease over time
This trial is a long-term follow-up for people who already took part in a previous study called ZiPP. It tests whether continuing treatment with zoledronate can help prevent Paget’s disease from developing or worsening.
GeelongAges Any age - NCT04046796Recruiting
Study genetics in identical twin who differ in symptoms
This study looks at DNA changes to explain why two identical (monozygotic) twins can have different symptoms. It may help clarify the cause of an unclear condition in one twin so the right diagnosis (and future treatment) can be found.
TübingenAges Any age - NCT05327972RecruitingPhase 2
Botox injections for painful degenerative rotator cuff disease
This Phase 2 study tests whether botulinum toxin (Botox) injections can reduce pain from long-lasting degenerative rotator cuff problems. You may be eligible if you have shoulder pain for over a month and ultrasound evidence of specific tendon irritation.
Paris, ParisAges 41 years+ - NCT04078412Enrolling by invitation
Registry for adults with nontuberculous lung infection
This is a research registry that collects information from adults diagnosed with nontuberculous mycobacterial (NTM) lung disease. It may help doctors better understand the disease and improve care over time.
SeoulAges 20 years+ - NCT04645251Recruiting
Join a UK registry for polycystic liver disease
This registry is for people with polycystic liver disease who have a high number of liver cysts. It helps collect information about your condition to better understand and support future care.
NijmegenAges 18 years+ - NCT02397824Recruiting
Teeth photo study for people with rare diseases
This study looks at how rare diseases can show up in the mouth and teeth, using pictures of your teeth. It may help doctors recognize dental signs earlier and better describe these rare conditions.
Strasbourg, AlsaceAges Any age - NCT03322306Enrolling by invitation
Genetic testing study for inherited neurological conditions
This trial looks for genetic causes of inherited (in family) neurological diseases by using genetic screening. If you might have an inherited neurological condition, this study may help explain why symptoms happen and guide future care.
Hong Kong, ShatinAges 18–80 - NCT07113795Enrolling by invitationEarly Phase 1
Chinese medicine and stem cells for Crohn's fistula
This trial tests a new approach that combines traditional Chinese medicine with stem cells to treat complex anal fistulas caused by Crohn's disease. It may help people whose Crohn's is not very active and who have not had major fistula surgery before.
Nanjing, JiangsuAges 18–60 - NCT02771236Recruiting
Study of inherited eye conditions in families
This study looks at families who have inherited (passed down) eye conditions, using eye exams and blood tests. It may help researchers understand what causes these conditions and find better ways to diagnose them.
La Jolla, CaliforniaAges 4–120 - NCT02924818Recruiting
Research study for adults with long-term breathing lung diseases
This study enrolls adults with chronic lung conditions like COPD, cystic fibrosis, bronchiectasis, or interstitial lung disease. It’s designed to learn more about these illnesses and to develop better ways to study or improve care.
ReimsAges 18 years+
Hear when a new General Population (no Specific Condition or Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for general population (no specific condition or disease)?
- Yes. Clin2 currently lists 10,803 recruiting general population (no specific condition or disease) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a general population (no specific condition or disease) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a general population (no specific condition or disease) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.